A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status

Active, not recruiting

Conditions

Psoriatic Arthritis
Rheumatoid Arthritis

Study type

Observational

Funder types

Industry

Identifiers

NCT05413044
IM101-816

Details and patient eligibility

About

The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.

Enrollment

4,300 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of RA or PsA
  • ≥18 years at index treatment initiation

Participants starting treatment with:

  • abatacept
  • non-targeted DMARDs
  • targeted DMARD

Exclusion criteria

- Not applicable

Trial design

4,300 participants in 3 patient groups

Abatacept Group
Description:
Participants with established RA or PsA and receiving abatacept.
Non-targeted Disease Modifying Anti-rheumatic Drug (DMARD) Group
Description:
Participants with established RA or PsA and not previously treated with any targeted DMARDs and who start treatment with a non-targeted DMARD.
Targeted DMARD Group
Description:
Participants with established RA or PsA and previously treated without abatacept who start treatment with targeted DMARDs.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems